StocksMedium•16 November 2026•
1 min read
Galectin Therapeutics Beats Q3 Estimates as Losses Narrow 69%
Key Facts
1Galectin Therapeutics announced its financial results for the quarter ended September 30, 2026.
2The company highlighted a significant reduction in total debt during the period.
3The company reported continued progress on its lead product candidate, belapectin.
Galectin Therapeutics reported a loss of $0.04 per share for the third quarter ended September 30, 2026. Benzinga reported that this figure represents a 69.23% improvement compared to the previous year and beat analyst estimates of a $0.05 loss per share.
The company concluded the quarter with a significant reduction in total debt while maintaining progress on its lead product candidate, belapectin. GALT closed at $3.05 on November 13, 2026, with the stock trading between a low of $2.93 and a high of $3.31 during that session.